Compare BOBS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOBS | ANAB |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | BOBS | ANAB |
|---|---|---|
| Price | $11.81 | $62.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $23.73 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.3M | 616.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $7.43 | $52.14 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $9.74 | $17.11 |
| 52 Week High | $23.11 | $73.30 |
| Indicator | BOBS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 48.23 |
| Support Level | $9.97 | $53.46 |
| Resistance Level | $12.15 | $70.26 |
| Average True Range (ATR) | 0.93 | 4.70 |
| MACD | 0.20 | -0.49 |
| Stochastic Oscillator | 52.87 | 35.15 |
Bobs Discount Furniture Inc operates as a furniture retailer offering a wide variety of merchandise assortments across several categories, including upholstery, case goods, bedding, and other. The company generates the majority of its revenue from the sale of its products through its retail stores.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).